Altre lingue Rani Therapeutics Holdings, Inc.

Azioni

RANI

US7530181004

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/04/2024			Variaz. 5gg	Var. 1 gen.
7,85 ^USD	+14,26%		+88,70%	+136,45%

27/03	RANI THERAPEUTICS HOLDINGS, INC. : Canaccord Genuity ancora positivo	ZM
25/03	RANI THERAPEUTICS HOLDINGS, INC. : HC Wainwright conferma il rating Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update	20/03
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	18/03
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	15/03
Rani Therapeutics : RT-111 Phase 1 Data Presentation	12/03
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)	05/02
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)	05/02
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)	09/01
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope	14/12
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist	14/12
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	01/12
Sector Update: Health Care	01/12
Rani Therapeutics Stock Climbs After Share Purchase by CEO	01/12
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update	08/11
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results	01/11
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform	01/11
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study	25/10/23
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration	25/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Rani Therapeutics Holdings, Inc.

Azioni

RANI

US7530181004

Altre lingue

Filtri